AlphaVax Announces New NIH Vaccine Grant for Influenza

AlphaVax announced that it has received a significant new vaccine development grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The new award provides a total of $6.5 million over a three-year period to support the first preclinical development and preparations for clinical stages of development of an influenza vaccine using the company's promising new vaccine technology, the ArV (AlphaVax replicon Vector) system.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19721120&full=1)